In July 2026, CITEST Diagnostics Inc. launched the Multiplex Respiratory Antigen Rapid Test, a professional use in-vitro diagnostic product built for quick, qualitative pathogen screening from human nasopharyngeal swab samples. Engineered with multiplex lateral-flow immunoassay technology, this detection cassette identifies common respiratory pathogens and supplies auxiliary diagnostic evidence for infectious respiratory diseases, with readable outcomes ready within 15 minutes with no complicated lab-based equipment.
Designed for practical professional diagnosis, the Multiplex Respiratory Antigen Rapid Test possesses prominent functional advantages. It adopts a dual-sample-well layout that can test for up to 10 analytes in one cassette. Customizable analyte combinations are available, covering Flu B, Flu A, HPIV1/3, HPIV2, HMPV, BP, HBoV, Adeno, MP, RhV, RSV, COVID-19 and Strep A to satisfy varied screening demands. No testing apparatus is needed for straightforward operation, and fast read results are obtainable in 15 minutes for time-saving and handy detection.
Constructed for dependable respiratory pathogen screening, this lateral-flow immunoassay test requires nasopharyngeal swab specimens and only basic operating skills. Its catalog number is RTRTCD(2-10)CI, each kit contains 20-test cassettes (20T). This product is restricted to professional in-vitro diagnostic application. Its detectable pathogens contain Adenovirus, human Parainfluenza virus, RSV, SARS-CoV-2, Mycoplasma pneumoniae, Rhinovirus, Influenza A/B, HMPV, Bordetella pertussis, Bocavirus and Group A Streptococcus, covering major bacterial and viral triggers for upper and lower respiratory-tract infections.
The Multiplex Respiratory Antigen Rapid Test meets market requirements for comprehensive multi-pathogen respiratory screening. By integrating maximum-analyte detection, configurable panels and instrument-free simple operation, the new-release cassette strengthens CITEST's standing as a reputable supplier of rapid diagnostic supplies, focusing on efficiency and comprehensive coverage for clinical respiratory infection screening.
